Bacteriuria

Summary

Bacteriuria (MONDO:0001882) is a disease and 26 clinical trials. Top therapeutic interventions include levofloxacin anhydrous, ofloxacin, and chlorhexidine. A subtype of urinary system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 26

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bacteriuria
Mondo ID	MONDO:0001882
MeSH	D001437
DOID	DOID:1412
ICD-11	626563645
UMLS	C0004659
MedGen	491
MedDRA	10004056
Is cancer (heuristic)	no

Also known as: bacteriuria · bacteriuria (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of urinary system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › bacteriuria

Related subtypes (19): ureteral disorder, pyuria, urinary tract obstruction, urethral disorder, kidney disorder, urinary bladder disorder, hyperglycinuria, hypercalciuria, absorptive, 2, hypercalciuria, absorptive, 1, megacystis-megaureter syndrome, postorgasmic illness syndrome, congenital urachal anomaly, urinary system neoplasm, urothelial hyperplasia, urolithiasis, urinary tract infection, meningitis-retention syndrome, paraneoplastic renal syndrome, idiopathic hypercalciuria

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 26.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	9
PHASE1	6
PHASE4	4
PHASE3	3
PHASE2	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00126698	PHASE4	COMPLETED	Prophylactic Antibiotics on Urethral Catheter Withdrawal
NCT01871753	PHASE4	COMPLETED	The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria
NCT02032394	PHASE4	UNKNOWN	Effect of Chlorhexidine on Bacteriuria
NCT02113774	PHASE4	UNKNOWN	The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients
NCT00258089	PHASE3	COMPLETED	A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections
NCT00258102	PHASE3	COMPLETED	A Study of the Safety and Effectiveness of Levofloxacin Compared With Lomefloxacin in the Treatment of Complicated Urinary Tract Infections
NCT01691430	PHASE3	COMPLETED	A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents
NCT01114347	PHASE2	COMPLETED	Prevention of Nosocomial E. Coli Infections After Placement of an Indwelling Catheter During Pelvic Surgery: an Evaluation of Cranberry Gel Capsules
NCT02575495	PHASE2	COMPLETED	A Randomized Control Trial of Antibiotic Treatment Duration For Asymptomatic Bacteriuria After Kidney Transplantation
NCT04985110	PHASE2	UNKNOWN	Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital
NCT06559618	PHASE1	RECRUITING	Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
NCT00093938	PHASE1	COMPLETED	Cranberry Juice for Preventing Bacteria in Urine During Pregnancy
NCT00717600	PHASE1	UNKNOWN	Bacteriuria Eradication Through Probiotics
NCT01033383	PHASE1	COMPLETED	Dosing Study of Cranberry Capsules for the Prevention of Bacteriuria in Nursing Home Residents
NCT02052674	PHASE1	WITHDRAWN	Retained Urine Volume and Bacteriuria in Traditional Versus Vented Urine Drainage Systems
NCT02277171	PHASE1	COMPLETED	Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters
NCT04230746	EARLY_PHASE1	WITHDRAWN	Effect of Antibiotics on Urinary Microbiome
NCT01143116	Not specified	COMPLETED	Reduction of Bacteriuria in Subjects Practicing Intermittent Catheterization
NCT01349738	Not specified	UNKNOWN	Asymptomatic Bacteriuria & Risk of Urinary Tract Infection in Renal Transplants
NCT01926756	Not specified	UNKNOWN	Does Straight Catheterization in Short Gynecologic Procedures Cause Bacteriuria?
NCT02797613	Not specified	COMPLETED	Restricted Reporting for Positive Urine Cultures
NCT02922868	Not specified	COMPLETED	Assessment of Infection Control, Practice Efficiency, and Health Economics of Sheathed Versus Standard Cystoscopy
NCT03131609	Not specified	COMPLETED	Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
NCT03816384	Not specified	WITHDRAWN	Effect of Active Drain Line Clearance on Catheter-Associated Bacteriuria
NCT04461262	Not specified	UNKNOWN	The Impact Of A Catheter Coating On Clinical Bacteriuria
NCT04658719	Not specified	UNKNOWN	A Pilot Study To Assess The Impact Of A Camstent Coated Catheter On Clinical Bacteriuria

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LEVOFLOXACIN ANHYDROUS	4	4
OFLOXACIN	4	2
CHLORHEXIDINE	4	1
CIPROFLOXACIN	4	1
POVIDONE-IODINE	4	1
CO-TRIMOXAZOLE	3	1
17	0	1